Table 1

Analysis of anti-Ro52 sera without evidence of anti-Ro60 by different anti-Ro52 and anti-Ro60 methods. Values shown in bold exceed the cut off value

ABCDEFGHIJKLMNOPQ
P, positive; N, negative; ND, not done; MCTD, mixed connective tissue disease; UCTD, undifferentiated connective tissue disease. A, Patient number; B, scan value of anti-Ro52 on INNO-LIA ANA (K1090); C, anti-Ro52 reactivity on HeLa-S100 immunoblot; D, anti-Ro52 reactivity on ELISA with recombinant Ro52 and Ro60 in equal concentrations (U/ml), cut off 5 U/ml; E, anti-Ro52 reactivity on ELISA with recombinant Ro52 under non-reducing conditions (U/ml), cut off 5 U/ml; F, anti-Ro52 reactivity on ELISA with recombinant Ro52 under reducing conditions (U/ml), cut off 5 U/ml; G, diagnosis; H, anti-dsDNA antibodies on Crithidia; I, other antibodies on INNO-LIA ANA (K1090); J, double immunodiffusion with thymus/spleen nuclear extract; K, detection of anti-SSA/Ro60 on HEp-2000 substrate; L, double immunodiffusion with natural Ro60; M, immunoblot with recombinant Ro60; N, immunoblot with natural Ro60; O, ELISA with natural SSA/Ro60; P, Varelisa with recombinant Ro52 and Ro60 in an unspecified ratio; Q, protein immunoprecipitation.
*Confirmation by at least one of the other anti-Ro52 detection methods.
†Anti-Ro60 reactivity demonstrated.
6584*97P 27 >100 37 SclerodermaNNNNNNNNN
6598*†95P 14 16 13.6 SclerodermaNAnti-Scl-70NPNNNPPND
6853*101P 14 13 NDRheumatoid arthritisNAnti-RNPANNNNNNDNND
7581*101N 6.8 13 9.6 SLENNNNNNNNN
7908*99P 5.8 7.7 >100 Rheumatoid arthritisNNNNNNNNND
8641*88P 80 100 >100 Sjögren's syndromeNNNNNDNDNDNND
8990*95P 3.2 2.7 29 SLENAntihistonesNNNNNNNN
10417*100P 50 >100 >100 SclerodermaNAnti-RNPA/CNNNNNNNN
10581†*66N 8.3 12 10 SclerodermaNAnti-RNPA/C/70NNNPPPNND
10746*107P 2.5 2.9 >100 SclerodermaNNNNNNNNN
11962*94P 1.1 32 2.2UCTDNAnti-CenpBNNNNNNNN
12882*98P 1.8 1.8 25 SclerodermaNAnti-CenpBNNNNDNDNDNND
12927*91P 13 22 25 MalignancyNNNNNNNNND
14216*93P 4.3 7.9 >100 DermatomyositisNNNNNDNDNNN
1450798N 2.8 2.5 3.5MalignancyNNNNNDNDNNND
15296*75N 4.5 7.8 8.2 Hepatitis C virusNNNNNDNDNNN
16120*93P 2.7 4.2 35 DermatomyositisNNNNNDNDNNND
17114*85P 7 9.3 13 Hepatitis C virusNNNNNDNDNNND
1737693N 2.4 2.7 3.6MCTDNAnti-RNPA/C/70NNNNDNDNNND
18208*103N 6.6 10 12 Psoriatic arthritisNNNNNDNDNNND